BioSpace News Archive

Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a medical device company known for its innovative and effective pain management solutions -- announced today that it is entering the final stages of clearance to receive a Taiwan FDA (TFDA) License for Medical Devices to distribute its flagship product, SofPulse® in Taiwan.

Clear Medical Imaging announces partnership with See-Mode Technologies to adopt See-Mode, an artificial intelligence (AI) software application that increases efficiencies within the ultrasound workflow by assessing ultrasound images, automatically detecting clinical pathologies, and building a complete report.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”) today announced its Vice President of R&D, Dr. Shiran Zimri, will deliver two presentations at the AD/PD™ 2023 Advances in Science & Therapy Conference which takes place March 28 - April 1, 2023 in Gothenburg, Sweden.

Capricor Therapeutics announced today that the Company presented the 18-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD).

Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, previously announced on March 15, 2023

Creative Biogene, one of the leading biotechnology products and services providers, is dedicated to enhancing the latest therapeutic technologies, including cell therapies, gene editing, immunotechnology, and vaccines.

Sparta Science announced an additional round of funding led by Spring Lake Equity Partners.

Predictmedix Inc. is excited to announce an update on the functionality and application of their technology across specific verticals.

Cidara Therapeutics, Inc. today reported financial results for the three months and full year ended December 31, 2022 and provided an update on its corporate activities and product pipeline.

Rodney Varner , CEO of Genprex, Inc. today commended The U.S. Food and Drug Administration’s (FDA) initiative that aims to expedite the development of gene therapies for patients with rare diseases.